Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck/Bayer's Vericiguat Could Bring A New Dynamic For Heart Failure

Executive Summary

The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.

You may also be interested in...



PARAGON-HF: Novartis Hangs Onto Hope For Entresto In HFpEF

Despite Phase III miss, Novartis is hopeful that the totality of the evidence will secure it at least a limited label expansion to a sizable but harder to treat portion of the heart failure market than Entresto already serves.

Novartis Plans Fast Entresto Launch Following FDA Approval

The company’s first-in-class angiotensin receptor neprilysin inhibitor was approved by FDA for heart failure with reduced ejection fraction July 7, earlier than expected.

Bayer/Merck Cardio Rx Collaboration Pumped Up By Consumer Deal

Merck sells consumer care business, but also buys into Bayer’s franchise of sGC modulators.

Related Companies

UsernamePublicRestriction

Register

SC141204

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel